1. Home
  2. |Insights
  3. |Federal Circuit Holds That Settlement Negotiations Are Not Privileged

Federal Circuit Holds That Settlement Negotiations Are Not Privileged

Client Alert | 2 min read | 04.17.12

In a decision last week that could have far reaching implications in "patent troll" cases, the Federal Circuit held that settlement negotiations are not immune from discovery, rejecting recognition of a "settlement negotiation privilege." 

In In re MSTG, Inc., a three-judge panel considered for the first time whether communications relating to reasonable royalties and damages are protected from discovery based on a settlement negotiation privilege. Applying the criteria for establishing privileges articulated by the Supreme Court, the panel determined that a settlement negotiation privilege is not warranted, and upheld a district court decision ordering production of settlement negotiation documents.

MSTG sued several  mobile device manufacturers and service providers claiming infringement of three patents allegedly covering 3G mobile communications technologies. MSTG extracted royalty-based settlements from all but one defendant. The remaining defendant sought those settlement agreements and all related communications in discovery, arguing that they were relevant to MSTG's royalty-based damages claims. MSTG produced the settlement agreements, but objected to production of the negotiation communications. 

In the meantime, however, MSTG served its expert's report on reasonable royalties. Therein, MSTG's expert admitted to relying on the agreements and the deposition testimony of a MSTG executive who indicated that the settlement agreements reflected "litigation-related compromises" and were therefore not proper comparisons for the hypothetical negotiation. Based on that testimony, the magistrate ordered MTSG to produce negotiation communications. The district judge affirmed, reasoning that because MSTG's expert relied on the testimony of MSTG's executive regarding MSTG's "business reasons" for entering into the settlement agreements, it would be unfair for MSTG to "then shield those reasons from further examination." MSTG filed a mandamus petition arguing that the Federal Circuit should fashion a new privilege in patent cases which would prevent discovery of litigation settlement negotiations related to reasonable royalties and damages. 

The panel, which included Chief Judge Rader, disagreed, considering the factors identified by the U.S. Supreme Court as relevant to the consideration of defining new privileges: (1) the policy decisions of the states; (2) whether Congress considered the question; (3) whether the privilege is listed among the nine evidentiary privileges recommended by the Advisory Committee of the Judicial Conference in its proposed Federal Rules of Evidence; and (4) whether the contemplated privilege advances a public good. The panel determined that the majority of the relevant factors weighed against establishment of a settlement negotiation privilege. The Court also noted that any such privilege would necessarily have numerous exceptions, and there are other effective methods to limit the scope of discovery to achieve the articulated public policy goals of protecting the sanctity of settlement discussions and promoting the compromise and settlement of disputes.

Corporate defendants, particularly those in troll cases, should take note of this important development. Early settling defendants are cautioned that their settlement negotiations may be discoverable, while later settling defendants may be encouraged to know that they can seek the settlement negotiations related to the reasonable royalties of previously settled Defendants during discovery.

Insights

Client Alert | 6 min read | 03.26.24

California Office of Health Care Affordability Notice Requirement for Material Change Transactions Closing on or After April 1, 2024

Starting next week, on April 1st, health care entities in California closing “material change transactions” will be required to notify California’s new Office of Health Care Affordability (“OHCA”) and potentially undergo an extensive review process prior to closing. The new review process will impact a broad range of providers, payers, delivery systems, and pharmacy benefit managers with either a current California footprint or a plan to expand into the California market. While health care service plans in California are already subject to an extensive transaction approval process by the Department of Managed Health Care, other health care entities in California have not been required to file notices of transactions historically, and so the notice requirement will have a significant impact on how health care entities need to structure and close deals in California, and the timing on which closing is permitted to occur....